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To estimate the proportion of methicillin-resistant 
Staphylococcus aureus (MRSA) isolates from humans that 
were sequence type (ST) 398, we surveyed 24 laboratories 
in 17 countries in Europe in 2007. Livestock-associated 
MRSA ST398 accounted for only a small proportion of MRSA 
isolates from humans; most were from the Netherlands, 
Belgium, Denmark, and Austria.
Livestock-associated methicillin-resistant Staphylo-coccus aureus (MRSA) was fi rst associated with human 
disease in 2003, when a MRSA clone associated with a 
reservoir in pigs and cattle was isolated from a human. This 
clone was not typable by pulsed-fi eld gel electrophoresis 
with SmaI macrorestriction digestion and belonged to 
multilocus sequence type (ST) 398 (1). Since then, rates 
of MRSA ST398 carriage have been high (25%–35%) 
for persons in the Netherlands who have frequent contact 
with pigs and veal calves, but associated illness is rare (2). 
However, in Europe, Asia, and the United States, invasive 
infections and a hospital outbreak of MRSA ST398 have 
been reported (3). We estimated the proportion of MRSA 
isolates from humans in Europe in 2007 that were ST398.
The Study
Questionnaires were mailed to 43 laboratories in 23 
European countries, selected on the basis of expertise and 
publications about MRSA. Questions asked for level of 
laboratory and typing methods used, number of MRSA 
isolates identifi ed in 2007, number of these isolates that 
were typed, and number of typed isolates that were MRSA 
ST398. MRSA isolates were considered to be ST398 if 
they 1) belonged to multilocus ST398, 2) were spa types 
t011, t034, t108, t567, t571, t588, t753, t898, t899, t1184, 
t1254, t1255, t1451, t1456, t1457, t2123, t2330, t2383, 
t2582, or t3013 (4; National Institute for Public Health and 
the Environment, unpub. data); or 3) were not typable by 
pulsed-fi eld gel electrophoresis with SmaI macrorestriction 
digestion. Laboratories were asked to report data on 
clinical isolates only (as opposed to screening isolates) and 
to provide the distribution by body site.
For each laboratory, the proportion of MRSA ST398 
among all typed MRSA isolates from humans and the 
95% Wilson confi dence interval (CI) were calculated. 
For laboratories that typed all MRSA isolates, χ2 testing 
compared proportions of isolates from various body sites 
for MRSA ST398 isolates and for other MRSA isolates.
For each country, we compared the proportions of 
MRSA ST398 among human MRSA isolates with number 
of pigs per km2, number of cattle <1 year of age (a surrogate 
for veal calves) per km2, and 2 indices multiplying 
these animal densities with human population densities. 
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Criteria were that a laboratory had to report >100 MRSA 
isolates and type >25% of those isolates, thus leaving 14 
national or regional laboratories from 12 countries. For 
Austria, data from 2 laboratories were pooled because 
these laboratories did not report duplicate isolates. For 
Denmark, only data on MRSA clinical isolates were 
used. Data for 2007 on midyear human population, pig 
production, and production of cattle <1 year of age were 
obtained from Eurostat (http://epp.eurostat.ec.europa.eu) 
except for pig production in Switzerland (Swiss Statistics, 
www.bfs.admin.ch) and Turkey (Turkstat, www.turkstat.
gov.tr). Land area was obtained from The World 
Factbook (www.cia.gov/library/publications/the-world-
factbook). For Germany, 1 region with high pig density 
was considered separately from the rest of the country. 
Data for this region (Eurostat regional Nomenclature of 
Territorial Units for Statistics code DEA3, corresponding 
to laboratory 8) were obtained from Eurostat, the 
Chamber for Agriculture Nordrhein-Westfalen: “Zahlen 
zur Landwirtschaft 2008” (www.landwirtschaftskammer.
de/wir/pdf/zahlen-landwirtschaft-2008.pdf), and the sta-
tistical offi ce of Nordrhein-Westfalen in Germany.
Questionnaires were received from 24 laboratories 
(response rate 56%) in 17 countries. Data from Malta and 
Slovenia and from 1 laboratory in Italy were not analyzed 
because these laboratories did not type MRSA isolates. 
Among the remaining 15 countries, 8 countries reported a 
combined total of 8,262 MRSA isolates with typing results, 
of which 142 (1.7%, 95% CI 1.5–2.0%) were MRSA ST398 
(Table 1). The proportions of MRSA ST398 per country 
were 0–11.9%; the countries with the highest proportion 
were the Netherlands (11.9%), Belgium (4.7%), Denmark 
(1.6%), and Austria (1.4%, pooled data). The proportion 
of isolates from blood was signifi cantly lower for MRSA 
ST398 than for other MRSA clinical isolates. No difference 
was observed for other body sites (Table 2).
The proportion of MRSA ST398 among human MRSA 
isolates correlated with pig density (Spearman ρ = 0.79, p 
= 0.001) and with the index combining this density with 
human population density (Spearman ρ = 0.76, p = 0.002). 
The proportion of MRSA ST398 among human MRSA 
isolates also correlated, although less signifi cantly, with 
the density of cattle <1 year of age (Spearman ρ = 0.61, 
p = 0.05) and with the index combining this density with 
human population density (Spearman ρ = 0.74, p = 0.01).
Conclusions
Livestock-associated MRSA ST398 was reported from 
8 of 15 European countries. Except for 4 countries and 1 
region in Germany, the proportion of MRSA ST398 among 
MRSA isolates from humans was <2%, suggesting that in 
2007 this livestock-associated clone contributed to only a 
small fraction of all MRSA in humans. A recent study of 
laboratories in 26 European countries during September 
2006–February 2007 found no MRSA ST398 among S. 
aureus isolates from persons with invasive infections (5).
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011 503
Table 1. Characteristics of laboratories that reported MRSA and livestock-associated MRSA ST398 isolates from human samples, 
Europe, 2007* 
Laboratory 
no. Country 
Type of 
laboratory 
Source of 
MRSA isolates 
No. MRSA 
isolates received
No. MRSA 
isolates typed 
MRSA ST398 isolates 
No. (%) 95% CI 
1 Austria National ref All 523 523 0 0–0.7 
2 Austria National ref All 586 586 16 (2.7) 1.7–4.4 
3 Belgium National ref All 329 149 7 (4.7) 2.3–9.4 
4 Czech Republic National ref Blood 37 10 0 0–27.8 
5 Denmark National ref All 659 659 14 (2.1) 1.3–3.5 
Denmark National ref Clinical 370 370 6 (1.6) 0.7–3.5 
6 Finland National ref All 1,323 1,323 1 (0.1) 0–0.4 
7 Germany National ref Clinical 1,293 1,293 9 (0.7) 0.4–1.3 
8 Germany Regional ref Clinical 866 866 37 (4.3) 3.1–5.8 
9 Greece National ref Clinical 336 336 0 0–1.1 
10 Hungary National ref All 365 63 0† NA
11 Iceland National ref Clinical 21 21 0 0–15.5 
12 Italy National ref Clinical 108 108 1 (0.9) 0.2–5.1 
13 Ireland National ref Clinical 832 696 0 0–0.5 
14 The Netherlands National ref Clinical 478 478 57 (11.9) 9.3–15.1 
15 The Netherlands Local Clinical 12 12 3 (25.0) 8.9–53.2 
16 Sweden National ref All 1,127 1,127 8 (0.7) 0.4–1.4
17 Switzerland Local Clinical 587 65 0† NA
18 Switzerland Regional ref All 182 182 0 0–2.1 
19 Switzerland Regional ref Clinical 64 64 0 0–5.7 
20 Switzerland Local All 80 78 0 0–4.7 
21 Turkey Local Clinical 198 60 0 0–6.0 
*MRSA, methicillin-resistant Staphylococcus aureus; ST398, sequence type 398; CI, confidence interval; ref, reference laboratory; NA, not applicable. 
†Not reported because laboratory typed <25% of MRSA isolates. 
MRSA ST398 has been isolated from human samples 
from Austria (5), the Netherlands (2), Belgium (6), Italy 
(7), Spain (8), Germany (9), Portugal (10), Denmark (11), 
the Czech Republic (12), Sweden (13), and France (14). 
This study demonstrated MRSA ST398 in human samples 
in Switzerland and Finland. Although few data have been 
published on the proportion of MRSA ST398 in Europe, 
Springer et al. (15) reported that during 2006 through mid-
2008, among 1,043 human MRSA isolates in Austria, 
21 (2.0%) were MRSA ST398, which is similar to the 
proportion (1.4%, pooled data) found in our study.
Among isolates from blood, a signifi cantly lower 
proportion were MRSA ST398 than other MRSA. This 
fi nding suggests that MRSA ST398 is associated with less 
severe disease, as indicated (5).
The proportion of MRSA ST398 among human MRSA 
isolates in European countries correlated with pig and veal 
calf densities and with an index combining pig or veal calf 
density and human population density. In addition to the 
well-documented risk factor of occupational exposure to 
pigs and veal calves, proximity of humans to pigs and veal 
calves may contribute to transmission of MRSA ST398 
from animals to humans. However, the fact that farms are 
not equally distributed throughout a country may explain 
the higher proportion of MRSA ST398 among MRSA 
isolates from humans in certain European countries and 
regions.
Use of readily available data bears some limitations. 
Laboratories were not randomly selected, which could 
result in selection bias. However, bias was limited because 
most laboratories were national reference laboratories 
that routinely collect MRSA isolates countrywide. Also, 
countries may have active national or local screening 
policies, may select which isolates to type, and may use 
typing techniques that are not always fully comparable. 
To minimize these variations, when possible we reported 
on data from clinical isolates only and excluded data from 
laboratories that reported few isolates and did not type 
most MRSA isolates. We also provided a list of MRSA 
spa types that at the time of the study had been identifi ed 
as corresponding to MRSA ST398. Other spa types and 
multilocus sequence types belonging to the livestock-
associated MRSA clones have been recently reported (4) 
and were not included in our study.
This cross-national prevalence study found livestock-
associated MRSA ST398 in human samples in several 
European countries. However, the relatively low proportion 
of MRSA ST398 among MRSA isolates from humans in 
most countries suggests that MRSA ST398 contributes to 
only a small fraction of all MRSA in humans.
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